# H.B. Fuller account plan

> H.B. Fuller is a NYSE-listed adhesives and sealants maker with FY2025 net revenue of $3,473.6 million and about 7,100 employees in 44 countries.

## At a glance

H.B. Fuller (NYSE: FUL), founded in 1887 in Minnesota, formulates, makes and sells adhesives, sealants and other specialty chemicals used in packaging, hygiene products, medical products, vehicles, electronics, solar, aerospace and construction. Products are mostly made in the region where they are sold, and no customer exceeds 10% of revenue. In fiscal 2025 (year ended November 29, 2025) net revenue was $3,473.6 million (-2.7%), adjusted EBITDA $620.7 million (17.9% of revenue) and net income attributable to the company $152.0 million. About 56% of revenue came from outside the U.S., and the company employed about 7,100 people in 44 countries. Celeste B. Mastin has been President and CEO since December 2022.

## Business units

- **Hygiene, Health and Consumable Adhesives (HHC)** (45% of FY2025 net revenue ($1,551.8 million)): Adhesives for assembly, packaging, converting, nonwoven, hygiene, health and beauty, flexible packaging, graphic arts and envelopes, plus the Medical Adhesives Technologies business built up with GEM and Medifill. FY2025 revenue rose 0.3% with a 15.7% adjusted EBITDA margin; in Q3 fiscal 2026 it grew 7.0% to $413.0 million. Led by James J. East, Executive Vice President.
- **Engineering Adhesives (EA)** (30% of FY2025 net revenue ($1,061.8 million)): High-performance adhesives for transportation, electronics, clean energy, aerospace and defense, textile, appliance and heavy machinery markets. It is the most profitable segment, with a 22.2% adjusted EBITDA margin in FY2025 and 23.8% in Q3 fiscal 2026, and has exited the lower-margin solar business. Led by João Magalhaes, Senior Vice President, since March 2025.
- **Building Adhesive Solutions (BAS)** (25% of FY2025 net revenue ($860.0 million)): Adhesives, sealants, tapes and application devices for commercial roofing, infrastructure, roads, telecom utilities, LNG plants, building envelope, HVAC insulation, woodworking and insulating glass; revenue tracks housing starts and construction activity. Q3 fiscal 2026 revenue rose 5.5% to $246.5 million. Led by M. Shahbaz Malik, Senior Vice President; in August 2026 Ancora Holdings Group made an unsolicited proposal for the segment, which the Board rejected.

## Strategic priorities

- **EBITDA margin above 20%**: Investor Day goals are 5% constant-currency growth and a 20% EBITDA margin, which the CFO dated to 2028; the Q3 fiscal 2026 adjusted EBITDA margin was 19.9%.
- **Medical as a fourth segment**: The pending Advanced Medical Solutions (AMS) acquisition grows medical adhesives from $68 million in revenue to approximately $370 million pro forma, about 10% of combined revenue, with EBITDA margins above 30% expected by 2030.
- **Quantum Leap footprint consolidation**: Plants go from 82 at end-2024 to about 62 at end-2026 and below 60 by end-2027, with a goal of 55, targeting about $75 million of annualized conversion cost savings by end-2030.
- **Deleveraging after AMS**: Leverage is expected at about 4x at the AMS close and is to return to the 2.5 to 3x target range within two years of closing; the CEO called deleveraging a very high priority.
- **Portfolio review**: After the August 2026 portfolio review, management is assessing whether it is the best owner of every market segment and says a divestment is being taken seriously.
- **Pricing against raw material inflation**: Price increases were announced in late March 2026; pricing exited Q3 fiscal 2026 at 7.6% as raw material prices stabilized at elevated levels after the Middle East supply disruption.

## Latest results

In Q3 fiscal 2026 (three months ended August 29, 2026) net revenue rose 5.2% to $938.2 million, with pricing adding 7.4% while volume fell 3.0%; organic revenue grew 4.4%. Gross margin improved 120 bp to 33.2%, adjusted EBITDA rose 9.4% to $186.7 million (19.9% margin) and diluted EPS was $1.44 vs $1.22. Over nine months revenue was $2,659.3 million (+3.1%) and net income $168.0 million. Guidance for FY2026, excluding AMS, is adjusted EBITDA of $655 to $670 million, adjusted EPS of $4.70 to $4.85 and operating cash flow of $300 to $325 million.

## Investments and deals

- **Advanced Medical Solutions acquisition**: Recommended cash offer agreed June 25, 2026 at 285 pence per share, an enterprise value of about GBP 715 million; shareholders approved on August 12, 2026 and closing is expected by the end of calendar 2026. Expected run-rate synergies are about $55 million.
- **European medical adhesives base**: GEM S.r.l. (Italy) and Medifill (Ireland) were bought in 2025 for about $196,990 thousand to establish a European headquarters for Medical Adhesives Technologies.
- **Fastener locking and precoating bolt-ons**: ND Industries Taiwan (February 2025), ND Industries Turkey (November 2025, about $7,902 thousand) and Dongguan Nako Technology (August 2026, CNY 70,000 thousand) were added to Engineering Adhesives.
- **Footprint restructuring and capex**: A footprint optimization programme approved in Q4 2025 is expected to cost $45.0 to $50.0 million through fiscal 2028; Quantum Leap needs $150 million of capital over its life. FY2025 capex was $142.3 million, with about $160.0 million expected in 2026.
- **Project ONE ERP**: The global SAP programme, costing $300 to $320 million in total, now runs 97% of revenue on one SAP instance and is winding down.

## Challenges and risks

- **Raw material cost and supply**: Raw materials are about 75% of cost of sales; after the Middle East conflict 52 force majeures remained in place in Q2 fiscal 2026 and the CEO does not expect a rapid recovery of global supply chains.
- **Falling volumes**: Q3 fiscal 2026 volume fell 3.0%; small and mid-sized customers are spacing out orders, and HHC volumes are hurt by GLP-1 drugs and low household formation.
- **Shareholder activism**: Ancora Holdings Group's rejected proposal for BAS and its threatened public campaign are a new risk factor; separating BAS would bring dis-synergies because it shares plants and solvent purchasing with other units.
- **Leverage and working capital**: Total debt was $2,054.5 million at Q3 fiscal 2026, inventory days rose to 88 from 78, and nine-month free cash flow was $40.9 million.
- **Litigation and regulation**: The Rouse grout case is set to settle for up to $75.0 million; PFAS regulation and OECD Pillar Two are named regulatory risks.

## What leadership says

> "deleveraging will be a very, very high priority for us" — Celeste Mastin, President and Chief Executive Officer, Q3 2026 earnings call, September 24, 2026

> "the possibility that we will divest something is something we're taking very seriously" — Celeste Mastin, President and Chief Executive Officer, Q3 2026 earnings call, September 24, 2026, on the annual portfolio review

> "we do not expect a rapid recovery of global supply chains" — Celeste Mastin, President and Chief Executive Officer, Q2 2026 earnings call, June 25, 2026

> "the second largest surgical tissue bonding company in the world" — Celeste Mastin, President and Chief Executive Officer, Q3 2026 earnings call, September 24, 2026, on the combination with AMS


## Where a supplier can help

- **Plant consolidation and real estate**: Quantum Leap closes about 20 plants by end-2026 and sells them; suppliers of manufacturing transfer, equipment relocation, automation and industrial real estate services fit this programme.
- **Raw material sourcing resilience**: With raw materials at about 75% of cost of sales and supply still disrupted, alternative specialty chemical suppliers and sourcing analytics tied to the pricing and supply challenge are relevant.
- **Medical integration**: Integrating AMS and the Peters Surgical consolidation, with $55 million of synergies targeted, needs regulatory, quality, cross-selling and integration support in medical devices.
- **Working capital and inventory**: The CFO targets an inventory reduction of at least 5 days; inventory planning and supply chain tools address the rise in inventory days to 88.
- **ERP finish and AMS onboarding**: Project ONE is winding down while AMS sites in the UK, Germany, France, Thailand and India join; system integration and data migration services map to that transition.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Form 10-K for the fiscal year ended November 29, 2025](https://www.sec.gov/Archives/edgar/data/39368/000143774926001767/ful20251130_10k.htm)

Annual report · 2026-01-22

- H.B. Fuller (NYSE: FUL), founded in 1887 in Minnesota, is a worldwide formulator, manufacturer and marketer of adhesives, sealants and other specialty chemicals; about 7,100 employees in 44 countries (about 2,500 in the U.S.) as of November 29, 2025.
- FY2025 net revenue was $3,473.6 million, down 2.7% (organic flat: pricing +0.8%, volume -0.8%; M&A -2.1%; currency -0.6%); gross margin rose to 31.1% from 29.8%.
- Adjusted EBITDA rose 4.5% to $620.7 million (17.9% of revenue vs 16.6%); net income attributable to H.B. Fuller $152.0 million (EPS $2.75 vs $2.30); operating cash flow $263.5 million, free cash flow $121.2 million.
- Three segments from FY2025: Hygiene, Health and Consumable Adhesives (45% of revenue), Engineering Adhesives (30%, the most profitable at 22.2% adjusted EBITDA margin) and Building Adhesive Solutions (25%), created after the sale of North America Flooring on December 2, 2024.
- Portfolio moves: GEM S.r.l. (Italy) and Medifill (Ireland) bought for about $197 million to build a European base for Medical Adhesives Technologies; ND Industries Taiwan added to Engineering Adhesives; HS Butyl (UK tapes) in BAS.
- About 56% ($2.0 billion) of revenue is generated outside the U.S.; raw materials are about 75% of cost of sales, mostly petroleum/natural-gas derivatives, so a 1% raw material change moves net income by about $12.6 million.
- Total debt $2,016.9 million; 2026 capex expected at about $160.0 million; Project ONE (SAP) total cost estimated at $300 to $320 million, still to be rolled out in Brazil and Asia Pacific.
- Risks flagged: raw material cost and supply, cyber, ERP execution, acquisitions/divestitures and the Quantum Leap global supply chain restructuring, international exposure (China, Turkey, Egypt, Brazil), tariffs, PFAS rules, and a $34.8 million accrual for the Rouse grout litigation from the divested flooring business.

### [Form 10-Q for the quarter ended August 29, 2026 (Q3 fiscal 2026)](https://www.sec.gov/Archives/edgar/data/39368/000143774926031145/ful20260831c_10q.htm)

Interim report · 2026-09-24

- Q3 FY2026 (quarter to August 29, 2026) net revenue $938.2 million, +5.2%: pricing +7.4%, volume -3.0%, currency +0.7%, acquisitions +0.1%; organic +4.4%.
- Gross margin 33.2% (+120 bp) on pricing and restructuring; adjusted EBITDA $186.7 million (+9.4%), 19.9% of revenue; net income $79.2 million, diluted EPS $1.44 vs $1.22.
- Nine months: revenue $2,659.3 million (+3.1%, organic +0.4%), adjusted EBITDA $486.5 million (+8.0%), net income $168.0 million.
- Segments in Q3: HHC $413.0 million (organic +6.4%, margin 17.6%), Engineering Adhesives $278.7 million (organic +0.7%, margin 23.8%), Building Adhesive Solutions $246.5 million (organic +5.2%, margin 18.2%).
- Pending acquisition of Advanced Medical Solutions Group plc (AMS) at 285 pence per share, equity value about GBP 659 million and enterprise value about GBP 715 million; AMS shareholders approved it on August 12, 2026, and closing is expected by calendar year-end.
- Financing: $3.0 billion of bridge commitments signed June 25, 2026; Term Loan A refinanced at $420.0 million and revolver raised to $800.0 million, both extended to July 2031.
- A new global footprint restructuring (approved Q4 2025) is expected to cost $45.0 to $50.0 million through fiscal 2028; $11.6 million incurred so far.
- New risk factor: Ancora's unsolicited August 12, 2026 proposal to buy the Building Adhesive Solutions segment, rejected by the Board, with Ancora threatening a public campaign.

### [H.B. Fuller Q3 2026 earnings call transcript](https://www.mitrade.com/insights/news/live-news/article-8-2114480-20260925)

Executive talk · Celeste Mastin, President and Chief Executive Officer · 2026-09-24

- CEO Celeste Mastin and CFO John Corkrean reported Q3 revenue +5.2% (organic +4.4%, pricing +7.4%), EBITDA $187 million (+9%) and an EBITDA margin of 19.9%, moving toward the target of greater than 20%.
- By business: HHC organic +6% (hygiene, beverage labeling, tape and label), EA about +5% excluding solar (aerospace, general industries; electronics softened on chip shortages), BAS +5% (roofing, insulating glass).
- Petrochemical supply chain dislocation from the Middle East conflict persists; raw material prices "have stabilized at elevated levels" and pricing continues to be raised "judiciously"; pricing exited the quarter at 7.6%.
- Project Quantum Leap: 82 plants at end-2024, about 62 by end-2026, below 60 by end-2027 and a goal of 55; about $75 million of annual savings targeted by 2030, $20 to $25 million more in 2027, $150 million of capex over the programme.
- FY2026 guidance (excluding AMS): adjusted EBITDA $655 to $670 million, adjusted EPS $4.70 to $4.85, operating cash flow $300 to $325 million.
- AMS acquisition on track to close by year-end; leverage to return to 2.5 to 3x within 2 years of closing; the combination makes H.B. Fuller the second largest surgical tissue bonding company in the world.
- Deleveraging is "a very, very high priority"; the company is asking whether it is "the best owner" of each market segment and takes a possible divestiture "very seriously".
- On Ancora's BAS bid: BAS is roughly 20% of revenue but 35% to 40% of solvent purchases and shares about two-thirds of its 25 to 30 plants, so a separation would create dis-synergies.

### [H.B. Fuller Q2 2026 earnings call (corrected transcript), incl. the offer for Advanced Medical Solutions](https://s26.q4cdn.com/617714526/files/doc_financials/2026/q2/CORRECTED-TRANSCRIPT_-H-B-Fuller-Co-FUL-US-Q2-2026-Earnings-Call-25-June-2026-10_30-AM-ET.pdf)

Executive talk · Celeste Mastin, President and Chief Executive Officer · 2026-06-25

- On the day it announced its cash offer for Advanced Medical Solutions (AMS), H.B. Fuller reported Q2 revenue +5.8% (organic +2.6%, pricing 3%), EBITDA $181 million (+9%), margin 19.1% and EPS $1.41 (+19%).
- AMS offer: GBP 2.85 per share, enterprise value about GBP 715 million, about 12.9x 2026 consensus EBITDA before synergies and less than 8x with them; AMS had fiscal 2025 revenue of about $302 million and adjusted EBITDA of about $54 million.
- Medical becomes a fourth segment, about 10% of combined revenue, growing the medical adhesives business from $68 million to about $370 million pro forma, with EBITDA margins above 30% expected by 2030.
- Synergies about $55 million ($20 million commercial, $35 million cost, of which about $14 million from AMS's Peters Surgical integration); about 50% by 2028; about 100 bp added to group EBITDA margin within 24 months.
- Leverage about 4x at close vs 3.1x now; target 2.5 to 3x within two years. Investor Day goals: 5% constant-currency growth and 20% EBITDA margin by 2028.
- Middle East supply disruption: prices raised from early April, high-single-digit pricing expected in H2; 52 force majeures still in place; raw material costs not expected to fully retrace.
- FY2026 guidance: adjusted EBITDA $650 to $675 million, adjusted EPS $4.60 to $4.90, operating cash flow $300 to $325 million.
- Aerospace growing more than 30% organically; Electronics and General Industries double-digit; Automotive down mid-single digits in all three regions.

## Questions about H.B. Fuller

### What does H.B. Fuller do?

H.B. Fuller formulates, makes and sells adhesives, sealants and specialty chemicals for packaging, hygiene, medical, transportation, electronics, aerospace and construction customers, through three segments: HHC, Engineering Adhesives and Building Adhesive Solutions.

### What is H.B. Fuller's revenue?

Net revenue was $3,473.6 million in fiscal 2025, with adjusted EBITDA of $620.7 million. In the first nine months of fiscal 2026 revenue was $2,659.3 million, up 3.1%.

### How many employees does H.B. Fuller have?

About 7,100 employees in 44 countries as of November 29, 2025, about 2,500 of them in the U.S.

### What is H.B. Fuller's strategy?

It aims for 5% constant-currency growth and a 20% EBITDA margin, is adding a medical segment through the AMS acquisition, and is consolidating plants under Quantum Leap while reviewing its portfolio.

### Who leads H.B. Fuller?

Celeste B. Mastin has been President and CEO since December 2022; John J. Corkrean is EVP and CFO.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
